Interleukine-1β (IL-1β), interleukine-6 (IL-6), tumor necrosis factor-α (TNF-α) and CRP could represent new therapeutic targets for anti-inflammatory treatment in endothelial dysfunction for reducing the risk of atherosclerotic cardiovascular disease (ASCVD) [15,16]. This evidence concerns the gene TNF and endothelial dysfunction.